Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody. 2012

Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
Bone Marrow Transplantation and Immunotherapy Program, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA. luml@karmanos.org

Human cytomegalovirus (CMV) reactivation and infection can lead to poor outcomes after allogeneic stem cell transplantation. We hypothesized that anti-CD3 activated T cells (ATCs) armed with chemically heteroconjugated anti-CD3 × polyclonal anti-CMV bispecific antibody (CMVBi) will target and eliminate CMV-infected cells. Arming doses of CMVBi as low as 0.01 ng/10(6) ATCs was able to mediate specific cytotoxicity (SC) directed at CMV-infected target cells significant above unarmed ATCs at mutiplicities of infection (MOI) between 0.01 and 1. At effector-to-target ratios (E:T) of 25:1, 12.5:1, 6.25:1, and 3.125:1, armed ATCs significantly enhanced killing of CMV-infected targets compared with unarmed ATCs. At an MOI of 1.0, the mean % SC directed at CMV-infected targets cells for CMVBi-armed ATCs at E:T of 3.12, 6.25, and 12.5 were 79%, 81%, and 82%, respectively; whereas the mean % SC for unarmed ATCs at the same E:T were all <20%. ATCs, Cytogam(®), or CMVBi alone did not lyse uninfected or CMV-infected targets. Co-cultures of CMVBi-armed ATCs with CMV-infected targets induced cytokine and chemokine release from armed ATCs. This nonmajor histocompatibility complex restricted strategy for targeting CMV could be used to prevent or treat CMV infections after allogeneic stem cell transplantation or organ transplantation.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D017252 CD3 Complex Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA). Antigens, CD3,CD3 Antigens,T3 Antigens,CD3 Antigen,T3 Antigen,T3 Complex,Antigen, CD3,Antigen, T3,Antigens, T3

Related Publications

Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
January 2018, Antimicrobial agents and chemotherapy,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
March 2024, Journal for immunotherapy of cancer,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
November 2023, Research square,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
November 2018, Scientific reports,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
January 2020, Frontiers in oncology,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
February 1993, Journal of immunology (Baltimore, Md. : 1950),
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
March 2018, Oncology reports,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
July 2021, Pediatric blood & cancer,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
December 2022, Annals of medicine,
Lawrence G Lum, and Mayur Ramesh, and Archana Thakur, and Subhashis Mitra, and Abhinav Deol, and Joseph P Uberti, and Philip E Pellett
January 2019, Journal of Cancer,
Copied contents to your clipboard!